Literature DB >> 30006918

Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis.

Arwa Mohammad Hassan1, Nessma Mohamed Ahmed Farghal1, Doaa Salah Hegab2, Wesam Salah Mohamed3, Hend Hassan Abd-Elnabi4.   

Abstract

Juvenile systemic lupus erythematosus (jSLE) is a multisystem autoimmune disease of unpredicted course and prognosis. Rates of organ involvement in SLE are higher in children, and overt lupus nephropathy is more often a presenting manifestation of SLE in children than adults. Inflammatory soluble chemokine CXC motif-ligand 16 (sCXCL16) is an important pathogenic mediator in inflammatory diseases as SLE. Herein, we aimed to evaluate serum level of sCXCL16 in jSLE patients in comparison to healthy controls and to correlate it with disease activity and extent of cutaneous and renal affection, to detect its possible role in disease pathogenesis. Serum level of sCXCL16 was determined by ELISA in 27 patients with jSLE (mean age 12.35 years ± 2.26 SD) in addition to 30 age- and sex-matched healthy controls and correlated with clinical and laboratory parameters in lupus group. Serum sCXCL16 was significantly higher in jSLE patients than controls (P ≤ 0.001), and it correlated positively with SLE disease activity, severity of lupus nephritis, 24-h urinary protein, anti-dsDNA titre, blood pressure, and ESR, while it correlated negatively with serum C3 levels. Serum sCXCL16 was higher in jSLE patients with alopecia and malar erythema. Serum sCXCL16 might play a role in inflammatory pathogenesis of jSLE particularly in periods of disease activity. It might serve as a future useful laboratory test for detection of jSLE activity, renal insult, and its severity which might limit the need for invasive renal biopsies in such a delicate patient population.

Entities:  

Keywords:  Activity; Chemokine; Cutaneous lupus; Juvenile; Lupus nephritis

Mesh:

Substances:

Year:  2018        PMID: 30006918     DOI: 10.1007/s10067-018-4203-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.

Authors:  María Concepción Izquierdo; Ana B Sanz; Sergio Mezzano; Julia Blanco; Susana Carrasco; María Dolores Sanchez-Niño; Alberto Benito-Martín; Marta Ruiz-Ortega; Jesús Egido; Alberto Ortiz
Journal:  Kidney Int       Date:  2012-01-25       Impact factor: 10.612

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  CXCL16 in kidney and cardiovascular injury.

Authors:  María Concepción Izquierdo; Catalina Martin-Cleary; Beatriz Fernandez-Fernandez; Usama Elewa; María D Sanchez-Niño; Juan Jesús Carrero; Alberto Ortiz
Journal:  Cytokine Growth Factor Rev       Date:  2014-05-02       Impact factor: 7.638

Review 4.  Systemic Lupus Erythematosus: A Review of the Clinical Approach to Diagnosis and Update on Current Targeted Therapies.

Authors:  Joanne Szczygiel Cunha; Katarzyna Gilek-Seibert
Journal:  R I Med J (2013)       Date:  2016-12-01

Review 5.  Chemokine: receptor structure, interactions, and antagonism.

Authors:  Samantha J Allen; Susan E Crown; Tracy M Handel
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 6.  The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned.

Authors:  Maria Teruel; Marta E Alarcón-Riquelme
Journal:  J Autoimmun       Date:  2016-08-10       Impact factor: 7.094

7.  Juvenile systemic lupus erythematosus: onset patterns and short-term outcome in Egyptian children, a single-center experience.

Authors:  M A Abdel-Hafez; H Abdel-Nabi
Journal:  Lupus       Date:  2015-07-28       Impact factor: 2.911

8.  Critical role of CXCL16 in hypertensive kidney injury and fibrosis.

Authors:  Yunfeng Xia; Mark L Entman; Yanlin Wang
Journal:  Hypertension       Date:  2013-09-23       Impact factor: 10.190

9.  The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10.

Authors:  Soeren Abel; Christian Hundhausen; Rolf Mentlein; Alexander Schulte; Theo A Berkhout; Neil Broadway; Dieter Hartmann; Radek Sedlacek; Sebastian Dietrich; Barbara Muetze; Bjoern Schuster; Karl-Josef Kallen; Paul Saftig; Stefan Rose-John; Andreas Ludwig
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Cutaneous manifestations of systemic lupus erythematosus in a tertiary referral center.

Authors:  Alakes Kumar Kole; Alakendu Ghosh
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more
  4 in total

1.  Th2 to Th1 Transition Is Required for Induction of Skin Lesions in an Inducible and Recurrent Murine Model of Cutaneous Lupus-Like Inflammation.

Authors:  Nazgol-Sadat Haddadi; Purvi Mande; Tia Y Brodeur; Kaiyuan Hao; Grace E Ryan; Stephanie Moses; Sharon Subramanian; Xhuliana Picari; Khashayar Afshari; Ann Marshak-Rothstein; Jillian M Richmond
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

2.  Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies.

Authors:  Asbjørn Christophersen; Stephanie Zühlke; Eivind G Lund; Omri Snir; Shiva Dahal-Koirala; Louise Fremgaard Risnes; Jørgen Jahnsen; Knut E A Lundin; Ludvig M Sollid
Journal:  Adv Sci (Weinh)       Date:  2021-09-08       Impact factor: 16.806

3.  Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever disease

Authors:  Taner Akyol; Tolga Düzenli; Alpaslan Tanoğlu
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

4.  Plasma chemokine CXC motif-ligand 16 as a predictor of renal prognosis in immunoglobulin A nephropathy.

Authors:  Ran Luo; Yi Yang; Yi-Chun Cheng; Dan Chang; Ting-Ting Liu; Yue-Qiang Li; Wei Dai; Mei-Ying Zuo; Yu-Lin Xu; Chun-Xiu Zhang; Shu-Wang Ge; Gang Xu
Journal:  Ann Transl Med       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.